Dr. Rhonda Patrick on broccoli sprouts: what the evidence says · JRE #1178

FACT CHECK // JRE #1178 // EXHIBIT LOG
THE JOE ROGAN EXPERIENCE
CLAIM CMRMCVD0STATUS: PUBLISHED
SUBJECT: BROCCOLI SPROUTS
Timestamp1:09:34
RulingNeeds Context

Not a true/false call. Every claim is logged with its sources; read the exhibits below.

// THE CLAIM · ON TAPE
So, you know, there's intervention trials in humans that it's, you know, men that were given broccoli sprout extract lowered their biomarker for prostate cancer by like 86% or lowered the doubling rate of it by 86%.
Dr. Rhonda Patrick@ 1:09:34
Watch on YouTubeJUMP TO 1:09:34

What the evidence says 01 / RECORD

Patrick appears to be referencing Cipolla et al. (2015), a double-blind, randomized, placebo-controlled trial of 78 men with rising PSA after radical prostatectomy who received 60 mg/day of stabilized sulforaphane or placebo for six months. The trial did report that PSA doubling time was 86% longer in the sulforaphane group than placebo (28.9 vs. 15.5 months), so the 86% figure itself is accurate to a real published result. However, PSA doubling time was a secondary outcome; the trial's pre-specified primary endpoint (change in log PSA slope from baseline to month 6) was not met. PSA doubling time is a surrogate biomarker, not a measure of cancer recurrence, metastasis, or survival. A 2023 systematic review of randomized controlled trials on sulforaphane in cancer found that results on PSA-related outcomes across the small number of available prostate cancer trials were inconsistent, that 75% of included trials carried a high risk of bias, and concluded that large-scale, robust trials are needed before clinical recommendations can be made. A separate small single-arm phase II trial of a different sulforaphane-rich extract (20 patients) found a smaller, though still statistically significant, lengthening of PSA doubling time (6.1 to 9.6 months).

/// factcheckjoerogan.com